Operations

Harpreet Singh, MD, touches on how the Commissioner’s National Priority Voucher program is accelerating regulatory review timelines without fundamentally changing how pivotal trials are designed.

Drawing on nearly two decades in biotech finance,Troy Ignelzi outlines why operational discipline, strategic storytelling, and long-term conviction have become essential survival tools in an increasingly unforgiving life sciences market.

Sandra Coufal, MD, CEO of Toragen, explains how the company’s Scientific Advisory Board was built to provide highly specialized expertise around HPV biology, immuno-oncology, and clinical development as TGN-S15 advances through trials.

Toragen’s partnership with the Bill & Melinda Gates Foundation highlights how global health priorities and commercial biotech strategy can align around one of the world’s deadliest HPV-driven cancers.

The takeaway leadership message from our May issue is clear: Future progress will come from those willing to rethink the machinery — not just the medicine.

BeOne Medicines’ John Oyler on building an oncology pharma power from a disruptive idea — and playing the long game on speed, science and scale.

Eli Lilly reported late-stage data showing patients with obesity were able to maintain long-term weight loss after transitioning from higher-dose injectable incretin therapies to lower-dose Zepbound or the company’s oral GLP-1 candidate Foundayo.

Rigel Pharmaceuticals has licensed Veppanu, positioning the company to expand into protein degradation-based oncology treatments for ESR1-mutated metastatic breast cancer.

Bristol Myers Squibb and Hengrui Pharma launch a multibillion-dollar collaboration spanning 13 oncology, hematology, and immunology programs to expand global drug development pipelines and accelerate early-stage clinical innovation.

Jamie Singer and Matt Flora discuss how cybersecurity threats in pharma are evolving beyond ransomware to include data extortion, supply chain attacks, and AI-driven risks.

GSK partners with Sino Biopharmaceutical’s CTTQ unit to support the launch of hepatitis B candidate Bepirovirsen in mainland China, leveraging a commercial network spanning more than 5,000 medical centers.

Incyte reports sustained 24-week efficacy and consistent safety data for Opzelura cream in moderate atopic dermatitis, supporting interest in nonsteroidal topical therapies for long-term disease control.

Angelini Pharma acquires Catalyst Pharmaceuticals in a $4.1 billion deal, expanding into the U.S. rare disease market and adding a portfolio of approved neuromuscular and neurological therapies.

Zentails announced the first dosage of Azenosertib administered in its phase III Aspenova trial to test azenosertib vs chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer.

Madrigal and Bayer strike billion-dollar deals to expand pipelines, with Madrigal licensing a PNPLA3-targeting siRNA for MASH and Bayer acquiring Perfuse Therapeutics to strengthen its ophthalmology portfolio.

BioNTech reports its first quarter finical results, including losses and declining Covid-19 revenue as the company accelerates its oncology investments and restructures its manufacturing footprint.

Jeff Golfman, founder and president of Send 123, in a conversation with Pharmaceutical Executive, discusses how rising geopolitical tensions around Iran and broader global disruptions are reshaping pharmaceutical and medical supply chains.

In the final part of his interview, Jeff Golfman discusses how data-driven supply chain mapping and collaborative procurement models can gain traction as companies move beyond cost-focused sourcing to strengthen resilience.

Sanofi is appointing Belén Garijo chief as director and chief executive officer after its annual meeting, underscoring the company's leadership and governance changes.

In the second part of his interview, Jeff Golfman notes how shelf-life constraints and shipping delays heighten drug shortage risk, prompting calls for diversified sourcing and larger inventory buffers.

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.

Teva will acquire Emalex to add ecopipam, a late-stage pediatric Tourette syndrome candidate, ahead of a planned 2026 filing.

In the first part of his interview, Jeff Golfman, notes how The Strait of Hormuz disruption exposes broader global supply chain contraction, raising risks for vaccines, cancer therapies, and other critical medicines.

At Asembia AXS26, Clarivate’s Dee Chaudhary outlined how U.S. drug pricing policy is rapidly shifting, driving more aggressive payer utilization management, tightening access controls, and increasing volatility in pharmaceutical pricing and forecasting.

Sun Pharma is set to acquire Organon in a $11.75 billion deal, while IMG Pharma enters a definitive agreement to purchase Matsumoto, signaling continued global consolidation and portfolio expansion across the pharmaceutical industry.